Navigation Links
Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
Date:12/1/2008

SAN DIEGO, Dec. 1 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) announced today the receipt of a $1.0 million milestone payment from Merck & Co., Inc. based on Merck's planned initiation of a Phase I clinical trial of an investigational plasmid DNA (pDNA) cancer vaccine. The candidate vaccine is based on Vical's DNA gene delivery technology and encodes human telomerase reverse transcriptase (hTERT). hTERT is the subject of separate license agreement.

"The breadth of applications for Vical's gene delivery technology continues to grow, and now encompasses vaccine candidates against infectious diseases and cancer, cancer immunotherapies, and gene-based angiogenesis for cardiovascular diseases," said Vijay B. Samant, Vical's President and Chief Executive Officer. "We are pleased that our long-standing partner Merck is expanding to a second clinical-stage evaluation of our technology in the cancer area."

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
2. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
3. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
4. Spine Institute of Louisiana Offers Cervical Spine Motion Preservation as an Alternative to Fusion Surgery
5. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
6. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
7. Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant
8. New Study Shows Listeria Vaccine for Cervical Cancer Found Safe
9. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
10. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
11. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/6/2009)....Y., Jan. 6 In recent controlled s...ty of Memphis , scientists found that the patented... first and only proven ingredient to increase leve...asing blood nitrate/nitrate (NOx) in human subject...nables an increase in blood flow to the skeletal m...
(Date:1/6/2009)...PANY, N.J., Jan. 6 Pacira Pharmace...ical company, announced today that enrollment,has...ials to evaluate the,safety and efficacy of a sin...(DepoBupivacaine) for prolonged postoperative anal...hoidectomy and in total knee,arthroplasty (TKA) a...
(Date:1/5/2009)...SE, Calif., Jan. 5 Women undergoin...ne medication to help support early,pregnancy, bu...his medication,can be painful for patients. Form...administered by subcutaneous injection or vaginal ... patient tolerance. , With patient well-bei...
(Date:12/27/2008)...S, Bermuda, Dec. 23 Warn...day that one of its subsidiaries and Mayne Pharma ... Hospira, Inc., have filed lawsuits against each o...Mylan Pharmaceuticals Inc. ("Mylan") and Impax Lab...or the District of New Jersey for infringement of ...
Breaking Medicine Technology:US Testing Proves Glyc'n Go(TM) Increases NO in the Blood Stream 2Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 2Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 3Fertility Physicians of Northern California Researchers Test New Forms of Progesterone Medication for Luteal Support During IVF 2Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 2Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 3NKTR 118 Shows Substantial Oral Bioavailability and Extended Half Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 1995 1NKTR 118 Shows Substantial Oral Bioavailability and Extended Half Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 1995 2NKTR 118 Shows Substantial Oral Bioavailability and Extended Half Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 1995 3NKTR 118 Shows Substantial Oral Bioavailability and Extended Half Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 1995 4NKTR 118 Shows Substantial Oral Bioavailability and Extended Half Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 1995 5NKTR 118 Shows Substantial Oral Bioavailability and Extended Half Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 1995 6UC San Diego researchers target tumors with tiny nanoworms 18615 1UC San Diego researchers target tumors with tiny nanoworms 18615 2UC San Diego researchers target tumors with tiny nanoworms 18615 3Linkwell Corporation Begins Training and Licensing Beijing Olympics Disinfection Teams 18614 1Linkwell Corporation Begins Training and Licensing Beijing Olympics Disinfection Teams 18614 2Linkwell Corporation Begins Training and Licensing Beijing Olympics Disinfection Teams 18614 3Linkwell Corporation Begins Training and Licensing Beijing Olympics Disinfection Teams 18614 4Catholic Charities Calls for Increased Support of Mothers in Need 3A 18612 1Catholic Charities Calls for Increased Support of Mothers in Need 3A 18612 2
...ed by FDA for long-term maintenance,treatment of C...bulized formoterol fumarate provides improved lung...anced patient quality of,life, and positive safety...e/ -- Data presented at the,International Conferen...ate that Perforomist (formoterol fumarate) Inhalat...
...s Blood Pressure in Obese and,Non-Obese Hypertensi...stCall/ -- Forest,Laboratories, Inc. today present... pooled analysis of nebivolol, a selective beta,1-...er review by,the U.S. Food and Drug Administration...m the two clinical studies show that,nebivolol dem...
Other Medicine Technology:Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 2Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 3Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 4Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 5Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 6Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 7Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy 2Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy 3Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy 4
(Date:1/8/2009)...ore effectively than Zocor , , THURSDAY,... review, U.S. health officials said Thursday that ...ial cholesterol-lowering drug Vytorin. , The U....significant difference in carotid artery thickness...ng the drug Zocor. , But, the agency reported, ...
(Date:1/8/2009)...tCall/ -- Allscripts-Misys Healthcare,Solutions, ...c. (Allscripts or,the Company), today announced i... ended November 30, 2008. , (Logo: http://...GO-b ) , The Company,s results for the thre...results from legacy Allscripts for the period of O...
(Date:1/8/2009)...swire/ -- The Pew Charitable Trusts announced toda...ical and food safety programs, in its Health &...merly deputy staff director and general counsel of...rks, brings nearly 25 years of experience in envir... , "We are excited to be joined by such an experi...
(Date:1/8/2009)...hristine Siu and Jason Brown, Ph.D. Promoted to Vi... STAMFORD, Conn., Jan. 8 Thomas, M...tal firm that invests in life science and medical ...n of three members of its investment team. Kathy ...u and Jason Brown have been promoted to Vice Presi...
Breaking Medicine News(10 mins):Health News:FDA Backs Cholesterol Drug Vytorin 2Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 2Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 3Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 4Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 5Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 6Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 7Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 8Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 9Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 10Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 11Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 12Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 13Health News:Veteran Environmental Health Expert Erik D. Olson to Join Pew 2Health News:Thomas, McNerney & Partners Promotes Three Members of Its Investment Team 2
... the most common and deadly cancer worldwide. Abou...this year out of which // 85% will die before 2010...tries, but it is fastly increasing in low and midd...lung cancer occurrence is smoking. Globally smokin...
...by the Temple University School of Medicine report...c floor disorders often do not report their discom... that eventually when they do report to their medi...ften complicated and of urogynecological nature. P...
...tories (RL) has received its first tentative appro... ) to manufacture // and market lamivudine tablets... retroviral agents (ARVs) to treat patients with H...fter a number of quality checks and inspections by...
...e identified an enzyme’s new role in aiding joint ...enzyme called cathepsin G can regulate the ability...l start the process of inflammatory conditions tha...athepsin G attracts accumulation of immune cells t...
Other Medicine News:Health News:Aggressive Tobacco taxation policy can reduce cigarette smoking, 2
...ct Complete® is a scientifically advanced nutr...ion for macular and full body health. MacularProte...nd other advanced research. It features a comprehe...d foundation of antioxidants, such as 10 mg of Flo...
Oculair (re-formulated Syntrx Complete) is a potent full-spectrum multiple vitamin/mineral/antioxidant dietary supplement that supports the normal aging process. It is designed to reflect the most re
Ocuvite® vitamin and mineral supplements contain 2 mg of Lutein 8 times more than the leading multivitamins. Ocuvite also contains vitamin antioxidants A, C and E, as well as the minerals zinc,
Most people take their eyes for granted. Like the rest of your body, your eyes need proper nutrition and care to help maintain eye health and vision as you age. In fact, research indicates proper nut
Medicine Products: